Journal List > Korean J Clin Microbiol > v.11(1) > 1038143

TOOLS
Kim, Kim, Ha, Song, and Lee: Evaluation of MicroScan MICroSTREP Plus Antimicrobial Susceptibility Panel for Testing Streptococcus pneumoniae
Original Article

Korean J Clin Microbiol 2008;11(1):18-22.

Published online: 20 April 2008

DOI: https://doi.org/10.5145/kjcm.2008.11.1.18

Evaluation of MicroScan MICroSTREP Plus Antimicrobial Susceptibility Panel for Testing Streptococcus pneumoniae

Han-Sung Kim1, 2, Jae-Seok Kim1, , Chae-Ok Ha2, Wonkeun Song1, Kyu Man Lee1

1Department of Laboratory Medicine, Hallym University College of Medicine, Seoul, Korea

2Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea

Jae-Seok Kim, Department of Laboratory Medicine, Hallym University College of Medicine, 445, Gil-dong, Gangdong-gu, Seoul 134-701, Korea. (Tel) 82-2-2224-2327, (Fax) 82-2-2224-2214, (E-mail) jaeseok@hallym.or.kr

Received 7 September 2007       Accepted 16 January 2008

Copyright © 2008 Korean Journal of Clinical Microbiology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The MicroScan MICroSTREP plus panel for susceptibility testing of various streptococci, including Streptococcus pneumoniae, has recently been introduced in Korea. The current study evaluated the usefulness of MicroScan MICroSTREP plus panel for antimicrobial susceptibility test of S. pneumoniae.

Methods

A total of 75 clinical isolates of S. pneumoniae were tested for antimicrobial susceptibility to penicillin, cefotaxime, ceftriaxone, meropenem, vancomycin, clindamycin, erythromycin, and levofloxacin with the MicroScan MICroSTREP plus panel and clinical and laboratory standard institute (CLSI) reference broth microdilution method. For 46 of 75 isolates, additional susceptibility tests to penicillin and cefotaxime were performed with Etest.

Results

The overall essential agreement of MICs (within one dilution of MICs) defined by the MicroScan MICroSTREP plus panel and reference method was 93.0%. Overall there were 11.7% minor, 0.7% major, and 0.7% very major interpretative category errors observed. The results of antibiotic susceptibility testing by Etest were similar to those obtained by the MicroScan MICroSTREP plus panel.

Conclusion

The MicroScan MICroSTREP plus panel, a commercial broth microdilution method, has a comparable accuracy to CLSI broth microdilution method for the resistance testing of S. pneumonia. This panel can be used for determining susceptibilities of S. pneumoniae to a wide variety of antimicrobial agents in clinical microbiology laboratories.

Keywords: Streptococcus pneumoniae, Antimicrobial susceptibility test, MicroScan, MICroSTREP plus panel

References

1. Spellerberg B and Brandt C. Streptococcus. Murray PR, Baron EJ, Jorensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. 9th ed.Washington, D.C.: ASM Press;2006. p. 412–9.
2. Jorgensen JH, McElmeel ML, Crawford SA. Evaluation of the Dade MicroScan MICroSTREP antimicrobial susceptibility testing panel with selected Streptococcus pneumoniae challenge strains and recent clinical isolates. J Clin Microbiol. 1998; 36:788–91.
3. Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J, Doern GV. the GRASP study group. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A B-hemolytic streptococci in 2002–03; Results of the multinational GRASP surveillance program. Int J Antimicrob Agents. 2005; 25:148–156.
4. Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis. 2005; 41:139–48.
5. Guthrie LL, Banks S, Setiawan W, Waites KB. Comparison of MicroScan MICroSTREP, PASCO, and Sensititre MIC panels for determining antimicrobial susceptibilities of Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1999; 33:267–73.
crossref
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. CLSI document M100-S16. Wayne, PA; CLSI. 2006.
7. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard–seventh edition. CLSI document M7-A7. Wayne, PA; CLSI. 2006.
8. Jorgensen JH, Ferraro MJ, McElmeel ML, Spargo J, Swenson JM, Tenover FC. Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test. J Clin Microbiol. 1994; 32:159–63.
crossref
9. Huh JW, Nah J, Lee SH, Pai CH. Evaluation of the E test for penicillin and cefotaxime susceptibility testing of Streptococcus pneumoniae. Korean J Lab Med. 1996; 16:330–9.
10. Diekema DJ, Beach ML, Pfaller MA, Jones RN. SENTRY Participants Group. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin Microbiol Infect. 2001; 7:152–7.
crossref
11. Lee H, Kim CK, Lee J, Lee SH, Ahn JY, Hong SG, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2005 and 2006. Korean J Clin Microbiol. 2007; 10:59–69.

Table 1.
Antimicrobial resistance properties of clinical isolates used in the study
  No. (%) of tested isolates
Susceptible Intermediate Resistant Total
Penicillin 26 (34.7) 11 (14.7) 38 (50.7) 75
Cefotaxime 51 (68.0) 17 (22.7) 7 (9.3) 75
Ceftriaxone 44 (58.7) 19 (25.3) 12 (16.0) 75
Meropenem 27 (36.0) 6 (8.0) 42 (56.0) 75
Erythromycin 15 (20.0) 1 (1.3) 59 (78.7) 75
Clindamycin 27 (36.0) 0 48 (64.0) 75
Levofloxacin 71 (94.7) 0 4 (5.3) 75
Vancomycin 64 (100) 0 0 64
Table 2.
Comparison of MICs determined by MICroSTREP plus panel with MICs determined by the CLSI reference method for clinical isolates of S. pneumoniae
  No. of MICs by MICroSTREP within indicated % Agreement (±1 dilution)
log2 of reference MICs
＞−2 −2 −1 0 ＋1 ＋2 ＞＋2
Penicillin 0 4 33 33 1 3 1 89.3
Cefotaxime 1 4 17 46 6 1 0 92.0
Ceftriaxone 1 6 31 37 0 0 0 90.7
Meropenem 0 10 21 43 0 1 0 85.3
Erythromycin 1 0 2 69 0 1 2 94.7
Clindamycin 0 0 11 59 2 2 1 96.0
Levofloxacin 0 1 19 53 2 0 0 98.7
Vancomycin 0 0 5 39 19 1 0 98.4
Table 3.
Interpretative category errors determined from a comparison of MICroSTREP plus panel and the CLSI reference method
  No. of tests No. (%) of Interpretative category errors
Very major Major Minor
Penicillin 75 0 0 9 (12.0)
Cefotaxime 75 2 (2.7) 0 12 (16.0)
Ceftriaxone 75 1 (1.3) 0 22 (29.3)
Meropenem 75 1 (1.3) 0 25 (33.3)
Erythromycin 75 0 2 (2.7) 1 (1.3)
Clindamycin 75 0 2 (2.7) 0
Levofloxacin 75 0 0 0
Vancomycin 64 0 0 0
Table 4.
Comparison of MICroSTREP with Etest using CLSI broth microdilution as the reference method
No. of MICs within indicated log2 of reference MICs % Agreement (±1 dilution) Interpretative category errors (%)
  −3 −2 −1 0 ＋1 ＋2 Very major Major Minor
Penicillin (n=46)                    
MICroSTREP 0 4 18 21 1 2 87.0 0 0 5 (10.9)
Etest 1 3 14 23 5 0 91.3 0 0 6 (13.0)
Cefotaxime (n=46)                    
MICroSTREP 0 1 11 30 4 0 97.8 0 0 6 (13.0)
Etest 0 2 7 31 6 0 95.7 0 0 6 (13.0)
TOOLS
Similar articles